---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-009272"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2022-01-31T23:59:59+00:00"
generated_at: "2026-06-27T13:26:19.823336+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Fennec Pharmaceuticals CCO Shubh Goel resigns; effective late February

## Summary
- Shubh Goel, chief commercial officer, tendered resignation on Jan 31, 2022.
- Goel will depart in late February 2022.
- CEO Rosty Raykov thanked Goel for contributions; company continues launch preparations for PEDMARK.
- PEDMARK is a treatment for cisplatin-induced ototoxicity in pediatric patients, pending approval.

## SEC filing metadata
- accession: 0001104659-22-009272
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2022-01-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465922009272/0001104659-22-009272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465922009272/tm224898d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-009272
- JSON: https://secwatch.observer/filing/0001104659-22-009272.json
- Plain text: https://secwatch.observer/filing/0001104659-22-009272.txt

## Key facts
- Executive change
  Shubh Goel resigned as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..
  - Action: resigned
  - Role: Chief Commercial Officer
  source text: On January 31, 2022 Fennec Pharmaceuticals Inc. announced the resignation of Chief Commercial Officer, Shubh Goel.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1211583/000110465922009272/0001104659-22-009272-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.